## Senate



General Assembly

File No. 419

February Session, 2018

Substitute Senate Bill No. 217

Senate, April 11, 2018

The Committee on Public Health reported through SEN. GERRATANA of the 6th Dist. and SEN. SOMERS of the 18th Dist., Chairpersons of the Committee on the part of the Senate, that the substitute bill ought to pass.

# AN ACT REQUIRING THE HEALTH INFORMATION TECHNOLOGY OFFICER TO ESTABLISH A WORKING GROUP TO EVALUATE ISSUES CONCERNING POLYPHARMACY AND MEDICATION RECONCILIATION.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 Section 1. (*Effective from passage*) (a) As used in this section:
- 2 (1) "Polypharmacy" means the simultaneous use of multiple drugs
- 3 by a patient to treat one or more ailments or conditions;
- 4 (2) "Medication reconciliation" means the process of comparing a
- 5 patient's admission, discharge and transfer medication orders to all of
- 6 the medications the patient has been taking for the purpose of
- 7 avoiding medication errors, including omission, duplication, dosing
- 8 errors and drug interactions; and
- 9 (3) "Prescribing practitioner" means a physician, dentist, podiatrist,
- 10 optometrist, physician assistant, advanced practice registered nurse or
- 11 nurse-midwife licensed by the state of Connecticut and authorized to
- 12 prescribe medication within the scope of such person's practice.

sSB217 / File No. 419

sSB217 File No. 419

13 (b) The Health Information Technology Officer designated under 14 section 19a-755 of the general statutes shall establish a working group 15 to evaluate issues concerning polypharmacy and medication 16 reconciliation. The members of the working group, who shall be

- 17 appointed by the Health Information Technology Officer, shall
- include, but need not be limited to, the following:
- 19 (1) Two experts in polypharmacy;
- 20 (2) Two experts in medical reconciliation;
- 21 (3) A representative of the Department of Consumer Protection;
- 22 (4) A pharmacist licensed under chapter 400j of the general statutes;
- 23 (5) A prescribing practitioner; and
- 24 (6) A member of the State Health Information Technology Advisory
- 25 Council established pursuant to section 17b-59f of the general statutes.
- 26 (c) Not later than July 1, 2019, the Health Information Technology
- 27 Officer shall report, in accordance with the provisions of section 11-4a
- of the general statutes, regarding the findings and recommendations of
- 29 the working group to the joint standing committees of the General
- 30 Assembly having cognizance of matters relating to public health and
- 31 general law.

This act shall take effect as follows and shall amend the following			
sections:			
Section 1	from passage	New section	

#### Statement of Legislative Commissioners:

In Section 1(b)(6), "Health Information Technology Advisory Council" was changed to "State Health Information Technology Advisory Council" for accuracy.

PH Joint Favorable Subst. -LCO

sSB217 File No. 419

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

#### **OFA Fiscal Note**

State Impact: None

Municipal Impact: None

Explanation

This bill, which establishes a polypharmacy and medication reconciliation working group, does not result in a fiscal impact as PA 17-236 prohibits transportation allowances for task force members.

The Out Years

State Impact: None

Municipal Impact: None

sSB217 File No. 419

### **OLR Bill Analysis**

**SB 217** 

AN ACT REQUIRING THE HEALTH INFORMATION TECHNOLOGY OFFICER TO ESTABLISH A WORKING GROUP TO EVALUATE ISSUES CONCERNING POLYPHARMACY AND MEDICATION RECONCILIATION.

#### **SUMMARY**

The Office of Legislative Research does not analyze Special Acts.

#### **COMMITTEE ACTION**

Public Health Committee

Joint Favorable Yea 27 Nay 0 (03/23/2018)